Abstract Visceral leishmaniasis (VL) is one of the severest forms of parasite borne diseases worldwide with a mortality rate second only to malaria. Treatment of VL patients with currently available chemotherapeutic agents poses problems of large scale failure, toxicity, prolonged hospitalization time, high treatment cost and drug resistance. However, most of these problems can be overcome by the use of liposomal formulations of Amphotericin B
Visceral leishmaniasis (VL) or kala-azar, a deadly and disseminated infection of the lymphoreticular system, is caused by the protozoan parasites of Leishmania donovani complex. An estimate of 0.2-0.4 million global VL cases are reported each year with more than 90 % of them occurring in India, Bangladesh, Sudan, South Sudan, Brazil and Ethiopia (Alvar et al. 2012) . In India, the state of Bihar, parts of Eastern Uttar Pradesh and West Bengal are endemic foci of VL (Verma et al. 2010 ) with an estimated annual incidence (cases from 2004 to 2008) ranging from 146,700 to 282,000 and mortality rate of 2.4 % (853/ 34,918) (Alvar et al. 2012) .
Conventional therapy for VL consists of pentavalent antimony but since 1990 there was a large scale failure of antimony treatment in the state of Bihar. This led to the introduction of Amphotericin B (AmB) as an active antileishmanial agent with long term cure rate of *98 %. However, the major disadvantage of this drug is its toxic side effects which could be significantly reduced by the introduction of liposomal formulation of Amphotericin B (L-AmB). Among the different L-AmB formulations studied, AmBisome can produce a cure rate of 89-100 % in Indian subcontinent depending on the doses administered (Mondal et al. 2010) . Of the two L-AmBs that have established safety and efficacy through clinical trials, AmBisome is imported and FUNGISOME is indigenous and would be economical for control programs. . Although India has the highest VL burden representing 25 % of global VL cases, it is an irony that they are not included in this donation program according to published reports (WHO 2013). However, this charity to less than 1 % of the total patients for a limited period of 5 years (MSF statement 2011) impacted undermining and pre-empt India's own superior alternative FUNGISOME whose development was supported through R&D funding from DBT and PATSER (Program Aimed at Technological Self-Reliance) of DSIR.
In fact, in India AmBisome kept on selling at prices much higher than the WHO proposed price of US $18 (roughly equivalent to Rs. 1,100/-) per vial. This price anomaly in addition to the limited supply of AmBisome for MSF, DNDi or other WHO mentioned VL programs encouraged the development and application of FUNGI-SOME and as the efforts continued the outcome of various clinical trials (Bodhe et al. 1999 ) and studies (Mondal et al. 2010 ) of VL treatment with FUNGISOME in the last 20 years has always been most promising. Considering all these facts FUNGISOME could be looked upon as a potential alternative to AmBisome not only in India but also from a global point of view.
